MIRM - Mirum Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Mirum Pharmaceuticals, Inc.

950 Tower Lane
Suite 1050
Foster City, CA 94404
United States
650 667 4085

Full Time Employees200

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher PeetzPres, CEO & Director1.09MN/A1979
Mr. Peter Radovich M.B.A., Ph.D.Chief Operating Officer732.15kN/A1978
Dr. Pamela Vig Ph.D.Head of R&D678.2kN/A1971
Ms. Lara Longpre MBA, MSCChief Devel. Officer678.2kN/A1970
Jolanda HoweSr. VP & Global ControllerN/AN/AN/A
Mr. Paul K. RossChief Compliance OfficerN/AN/AN/A
Ms. Erin CampanySr. VP of HRN/AN/A1968
Dr. Ian Clements Ph.D.ConsultantN/AN/A1969
Ms. Vinita P. KumarSr. vice Pres of QualityN/AN/AN/A
Dr. Jean-Luc Girardet Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Corporate Governance

Mirum Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2023 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.